Emergent BioSolutions Inc. reported $789M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $789M (to Q3 2025). Net income: −$177M, trailing twelve months to Q2 2026. Free cash flow: $86M, trailing twelve months to Q2 2026. Operating margin: 13%, trailing twelve months to Q3 2025.

EBSEmergent BioSolutions Inc.

Healthcare

$6.81-31% 1Y

$6.81

$4.4552 weeks$13.90

EBS as reported

Emergent BioSolutions Inc. reported $789M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed.

$789M

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: −$177M
Net income · −227% year on year · trailing twelve months to Q2 2026
Free cash flow: $86M
Free cash flow · −45% year on year · trailing twelve months to Q2 2026
Operating margin: 13%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for EBS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$789M	n/a	Q3 2025
Net income	−$177M	−227%	Q2 2026
EPS	−$3.47	−241%	Q2 2026
Gross margin	54%	n/a	Q3 2025
Operating margin	13%	n/a	Q3 2025
Net margin	7.0%	n/a	Q3 2025
ROE	−7.6%	n/a	Q2 2026
ROA	−1.8%	n/a	Q2 2026
ROIC	4.2%	n/a	Q2 2026
Free cash flow	$86M	−45%	Q2 2026
P/E	18.5	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.